Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Integrin antagonists as therapeutics for inflammatory diseases.

Vanderslice P, Woodside DG.

Expert Opin Investig Drugs. 2006 Oct;15(10):1235-55. Review.

PMID:
16989599
2.

New approaches to blockade of alpha4-integrins, proven therapeutic targets in chronic inflammation.

Kummer C, Ginsberg MH.

Biochem Pharmacol. 2006 Nov 30;72(11):1460-8. Epub 2006 Jul 25. Review.

PMID:
16870156
3.

Cell adhesion antagonists: therapeutic potential in asthma and chronic obstructive pulmonary disease.

Woodside DG, Vanderslice P.

BioDrugs. 2008;22(2):85-100. Review.

PMID:
18345706
4.

Interfering with leukocyte integrin activation--a novel concept in the development of anti-inflammatory drugs.

Hilden TJ, Nurmi SM, Fagerholm SC, Gahmberg CG.

Ann Med. 2006;38(7):503-11. Review.

PMID:
17101541
5.

Alpha 4 integrin antagonists.

Jackson DY.

Curr Pharm Des. 2002;8(14):1229-53. Review.

PMID:
12052218
6.

Targeting leukocyte integrins in human diseases.

Yonekawa K, Harlan JM.

J Leukoc Biol. 2005 Feb;77(2):129-40. Epub 2004 Nov 17. Review.

7.

Drugs, inflammation and cell adhesion receptors.

Sánchez-Madrid F, González-Amaro R.

Expert Opin Pharmacother. 2001 Jan;2(1):3-17. Review.

PMID:
11336564
8.

Small molecule antagonists of alpha4 integrins: novel drugs for asthma.

Lobb RR, Adams SP.

Expert Opin Investig Drugs. 1999 Jul;8(7):935-45.

PMID:
15992095
9.

The integrin alpha 4 beta 1 (VLA-4) as a therapeutic target.

Elices MJ.

Ciba Found Symp. 1995;189:79-85; discussion 85-90, 174-6. Review.

PMID:
7587639
10.

Potent in vivo suppression of inflammation by selectively targeting the high affinity conformation of integrin α4β1.

Vanderslice P, Woodside DG, Caivano AR, Decker ER, Munsch CL, Sherwood SJ, Lejeune WS, Miyamoto YJ, McIntyre BW, Tilton RG, Dixon RA.

Biochem Biophys Res Commun. 2010 Oct 1;400(4):619-24. doi: 10.1016/j.bbrc.2010.08.114. Epub 2010 Aug 31.

PMID:
20807504
11.

Anti-adhesion molecule therapies in inflammatory bowel disease: touch and go.

Stefanelli T, Malesci A, De La Rue SA, Danese S.

Autoimmun Rev. 2008 May;7(5):364-9. doi: 10.1016/j.autrev.2008.01.002. Epub 2008 Feb 12. Review.

PMID:
18486923
12.

Vascular integrins in tumor angiogenesis: mediators and therapeutic targets.

Alghisi GC, Rüegg C.

Endothelium. 2006 Mar-Apr;13(2):113-35. Review.

PMID:
16728329
13.

Small molecule antagonists of integrin receptors.

Perdih A, Dolenc MS.

Curr Med Chem. 2010;17(22):2371-92. Review.

PMID:
20491638
14.

Targeting integrin structure and function in disease.

Staunton DE, Lupher ML, Liddington R, Gallatin WM.

Adv Immunol. 2006;91:111-57. Review.

PMID:
16938539
15.

Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases?

Davenport RJ, Munday JR.

Drug Discov Today. 2007 Jul;12(13-14):569-76. Epub 2007 Jun 26. Review.

PMID:
17631252
16.
17.

The integrin family of cell adhesion molecules has multiple functions within the CNS.

Milner R, Campbell IL.

J Neurosci Res. 2002 Aug 1;69(3):286-91. Review.

PMID:
12125070
18.

Function and antagonism of beta3 integrins in the development of cancer therapy.

Sheldrake HM, Patterson LH.

Curr Cancer Drug Targets. 2009 Jun;9(4):519-40. Review.

PMID:
19519320
19.

Emerging drugs for asthma.

Walsh GM.

Expert Opin Emerg Drugs. 2008 Dec;13(4):643-53. doi: 10.1517/14728210802591378 . Review. Erratum in: Expert Opin Emerg Drugs. 2009 Mar;14(1):205.

PMID:
19046132
20.

Integrins as therapeutic targets: lessons and opportunities.

Cox D, Brennan M, Moran N.

Nat Rev Drug Discov. 2010 Oct;9(10):804-20. doi: 10.1038/nrd3266. Review.

PMID:
20885411
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk